Given that the renin-angiotensin system is frequently activated in patients with nonalcoholic fatty liver disease (NAFLD) and that candesartan significantly attenuates liver fibrosis in obese mice and type 2 diabetes23,31, our findings suggest that candesartan suppresses macrophage infiltration and hepatic inflammation by normalizing intracellular Ca2+ homeostasis. This evidence concerns the gene REN and Hepatic fibrosis.